期刊
JOURNAL OF BIOLOGICAL CHEMISTRY
卷 285, 期 15, 页码 11178-11187出版社
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M109.092973
关键词
-
资金
- National Institutes of Health through the NINDS [K08NS52550]
- Deater Foundation
- MRC
- Muscular Dystrophy Campaign
- Hartmann Muller Foundation
- Herzog-Egli Foundation
- Olga Mayenfisch Foundation
- Foundation for Scientific Research (University of Zurich)
- German Society for Clinical Chemistry
- Laboratory Medicine (DGKL)
- European Commission [LSHM-CT-2006-037631]
- MRC [G0802760, G0601943] Funding Source: UKRI
- Medical Research Council [G0601943, G0802760] Funding Source: researchfish
HSAN1 is an inherited neuropathy found to be associated with several missense mutations in the SPTLC1 subunit of serine palmitoyltransferase (SPT). SPT catalyzes the condensation of serine and palmitoyl-CoA, the initial step in the de novo synthesis of sphingolipids. Here we show that the HSAN1 mutations induce a shift in the substrate specificity of SPT, which leads to the formation of the two atypical deoxy-sphingoid bases (DSBs) 1-deoxy-sphinganine and 1-deoxymethyl-sphinganine. Both metabolites lack the C-1 hydroxyl group of sphinganine and can therefore neither be converted to complex sphingolipids nor degraded. Consequently, they accumulate in the cell, as demonstrated in HEK293 cells over-expressing mutant SPTLC1 and lymphoblasts of HSAN1 patients. Elevated DSB levels were also found in the plasma of HSAN1 patients and confirmed in three groups of HSAN1 patients with different SPTLC1mutations. The DSBs show pronounced neurotoxic effects on neurite formation in cultured sensory neurons. The neurotoxicity co-occurs with a disturbed neurofilament structure in neurites when cultured in the presence of DSBs. Based on these observations, we conclude that HSAN1 is caused by a gain of function mutation, which results in the formation of two atypical and neurotoxic sphingolipid metabolites.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据